Trodelvy - Beechwood Capital

Drug Profile

ModalityADC

RouteIV

Therapy AreaOncology

Launch2020-04-22

US LOE2032-04-22

Peak Sales Est$4000M

Formulations[{"id":"trodelvy-iv","route":"IV","setting":"INFUSION_CENTER","frequency":"Weekly (Days 1,8 of 21-da

Companies

GILD (ORIGINATOR)100%

Expert: Sacituzumab govitecan: anti-TROP2 antibody conjugated to SN-38 topoisomerase I inhibitor.

Everyday: Antibody that delivers chemotherapy directly to cancer cells expressing TROP2.

Targets: ["TROP2"]

Indication	Stage	Key Study	Regional Status
mTNBC 2L+	APPROVED	ASCENT	[{"stage":"APPROVED","region":"US","approval_date":"2020-04-22"}]
HR+/HER2- mBC	APPROVED	TROPiCS-02	[{"stage":"APPROVED","region":"US","approval_date":"2023-02-03"}]
mUC 2L+	APPROVED	TROPHY-U-01	[{"stage":"APPROVED","region":"US","approval_date":"2021-04-13"}]
mTNBC 1L	PHASE3	ASCENT-03 (w/ Keytruda)	—
First-line mTNBC (non-CPI)	FILED	ASCENT-03	—
First-line PD-L1+ mTNBC	FILED	ASCENT-04/KEYNOTE-D19	—
First-line HR+/HER2- mBC	PHASE3	ASCENT-07	—

Trodelvy - 1L NSCLC - Ph3 - Topline (EVOKE-03) Q2 2026

Trodelvy - 1L mTNBC - FDA Approval H1 2026

Trodelvy - 1L HR+/HER2- mBC - Ph3 - OS Data (ASCENT-07) 2026

Trodelvy - 1L mTNBC (non-CPI) - FDA Approval (ASCENT-03) H2 2026

Trodelvy + Keytruda - 1L PD-L1+ mTNBC - FDA Approval (ASCENT-04) H2 2026

TROP2-directed ADC approved in mTNBC, HR+/HER2- mBC, mUC. Trodelvy + Keytruda Phase 3 positive in 1L mTNBC (May 2025).